Plasma homocysteine, oxidative stress and endothelial function in patients with Type 1 diabetes mellitus and microalbuminuria

Diabetic Medicine

Volumn 23, Issue 12, 2006, Pages 1350-1356

  Wotherspoon, F ^a,d   Laight, D W ^b   Browne, D L ^a   Turner, C ^c   Meeking, D R ^a   Allard, S E ^a   Munday, L J ^a   Shaw, K M ^a   Cummings, M H ^a  

^a QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^b UNIVERSITY OF PORTSMOUTH   (United Kingdom)

^c GUY S HOSPITAL   (United Kingdom)

^d DERRIFORD HOSPITAL   (United Kingdom)

Author keywords

Endothelium; Homocysteine; Oxidative stress; Type 1 diabetes mellitus; Vascular disease

Indexed keywords

ACETYLCHOLINE; ANTIOXIDANT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUTATHIONE; HOMOCYSTEINE; NITROPRUSSIDE SODIUM;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD FLOW; CARDIOVASCULAR RISK; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOTHELIUM; FEMALE; HUMAN; HYPERHOMOCYSTEINEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MICROALBUMINURIA; OXIDATIVE STRESS;

ADULT; ALBUMINURIA; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; ENDOTHELIUM, VASCULAR; FEMALE; HOMOCYSTEINE; HUMANS; MALE; OXIDATIVE STRESS;

EID: 33751246736     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2006.01980.x     Document Type: Article

References (39)

1. Deckert T, Poulson J, Larsen M. Prognosis of diabetics with diabetes onset before the age of thirty-one. Survival, causes of death and complications. Diabetologia 1978; 14: 363-377.
2. Stephenson J, Kenny S, Stevens L, Fuller J, Lee E. Proteinuria and mortality in diabetes: the WHO multinational study of vascular disease in diabetes. Diabet Med 1995; 12: 149-155.
3. Wilcken DEL. Novel risk factors for vascular disease: the homocysteine hypothesis of cardiovascular disease. J Cardiovasc Risk 1998; 5: 217-221.
4. Welch G, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998; 338: 1042-1050.
5. Vaccaro O, Perna AF, Mancini FP, Iovine C, Cuomo V, Sacco M et al. Plasma homocysteine and microvascular complications in Type 1 diabetes. Nutr Metab Cardiovasc Dis 2000; 10: 297-304.
6. Chico A, Perez A, Cordoba A, Arcelus R, Carreras G, de Leiva A et al. Plasma homocysteine is related to albumin excretion rate in patients with diabetes mellitus: a new link between diabetic nephropathy and cardiovascular disease? Diabetologia 1998; 41: 684-93.
7. Hultberg B, Agardh E, Andersson A, Brattstrom L, Isaksson A, Israelsson B et al. Increased levels of plasma homocysteine are associated with nephropathy, but not severe retinopathy in Type 1 diabetes mellitus. Scand J Clin Lab Invest 1991; 51: 1991.
8. Hofmann MA, Kohl B, Zumbach MS, Borcea V, Beirhaus A, Henkels M et al. Hyperhomocyst(e)inemia and endothelial dysfunction in IDDM. Diabetes Care 1998; 21: 841-848.
9. Stehouwer C, Lambert J, Donker A, Van Hinsbergh V. Endothelial dysfunction and pathogenesis of diabetic angiopathy. Cardiovasc Res 1997; 34: 55-68.
10. Behrendt D, Ganz P. Endothelial function. From vascular biology to clinical applications. Am J Clin Cardiol 2002; 90: L40-48.
11. Bellamy MF, McDowell IFW, Ramsey MW, Brownlee M, Newcombe RG, Lewis MJ. Oral folate enhances endothelial function in hyperhomocysteinuric subjects. Eur J Clin Invest 1999; 29: 659-662.
12. Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest 1996; 98: 5-7.
13. Heinecke J, Rosen H, Suzuki L, Chait A. The role of sulphur-containing amino acids in superoxide production and modification of low-density lipoprotein by arterial smooth muscle cells. J Biol Chem 1987; 262: 10098-10103.
14. Jones B, Rose F, Tudball N. Lipid peroxidation and homocysteine induced toxicity. Atherosclerosis 1994; 105: 165-170.
15. Upchurch G, Welch G, Fabian A, Freedman J, Johnson J, Keaney J et al. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem 1997; 272.
16. Poston L, Taylor P. Endothelium-mediated vascular function in insulin-dependant diabetes mellitus. Clin Sci 1995; 88: 245-255.
17. Browne D, Meeking D, Shaw K, Cummings M. Endothelial dysfunction and pre-symptomatic atherosclerosis in Type 1 diabetes - pathogenesis and identification. Br J Diab Vasc Dis 2003; 3: 27-34.
18. Elliott T, Cockcroft J, Groop P-H, Viberti G, Ritter J. Inhibition of nitric oxide synthesis in forearm vasculature of insulin-dependant diabetic patients: blunted vasoconstriction in patients with microalbuminuria. Clin Sci 1993; 85: 687-693.
19. Dogra G, Rich L, Stanton K, Watts G. Endothelium-dependent and independent vasodilation studied at normoglycaemia in Type 1 diabetes mellitus with and without microalbuminuria. Diabetologia 2001; 44: 593-601.
20. Johnstone M, Creager S, Scales K, Cusco J, Lee B, Creager M. Impaired endothelium-dependant vasodilation in patients with insulin-dependant diabetes mellitus. Circulation 1993; 88: 2510-2526.
21. Meeking D, Browne D, Allard S, Munday J, Chowienczyk P, Shaw KM et al. Effects of cyclo-oxygenase inhibition on vasodilatory response to acetylcholine in patients with Type 1 diabetes and non-diabetic subjects. Diabetes Care 2000; 23: 1-4.
22. Powrie JK, Watts GF, Ingham JN, Taub NA, Talmud PJ, Shaw KM. Role of glycaemic control in development of microalbuminuria in patients with insulin-dependent diabetes. Br Med J 1994; 309: 1608-1612.
23. Hokanson D, Sumner D, Strandness D. An electronically calibrated plethysmograph for direct measurement of limb blood flow. IEEE Trans Biomed Eng 1975; 121: 1-27.
24. Calver A, Collier J, Vallance P. Inhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetes. J Clin Invest 1992; 90: 2548-2554.
25. Wilson J, Kapoor S. Contribution of prostaglandins to exercise-induced vasodilation in humans. Am J Physiol 1993; 265: H171-173.
26. Laight D, Gunnarsson P, Kaw A, Anggard E, Carrier M. Physiological microassay of plasma total antioxidant status in a model of endothelial dysfunction in the rat following experimental oxidant stress in vivo. Exp Toxicol Pharmacol 1999; 7: 27-31.
27. Tietze F. Enzymic method for quantitative determination of nanaogram amounts of total and oxidized glutathione. Anal Biochem 1968; 27: 502-522.
28. Walker H, Jackson G, Ritter J, Chowienczyk P. Assessment of forearm vasodilator responses to acetylcholine and albuterol by strain gauge plethysmography: reproducibility and influence of strain gauge placement. Br J Clin Pharmacol 2001; 51: 225-229.
29. Altman P. Practical Statistics for Medical Research. London: Chapman and Hall, 1991.
30. Chiarelli F, Pomilio M, Mohn A, Tumini S, Vanelli M, Morgese G et al. Homocysteine levels during fasting and after methionine loading in adolescents with diabetic retinopathy and nephropathy. J Pediatrics 2000; 137: 386-392.
31. Marra G, Cotroneo P, Pitocco D, Manto A, Di Leo M, Ruotolo V et al. Early increase of oxidative stress and reduced antioxidant defences in patients with uncomplicated Type 1 diabetes. Diabetes Care 2002; 25: 370-375.
32. Ferretti G, Bacchetti T, Busni D, Rabini RA, Curatola G. Protective effect of paraoxonase activity in high-density lipoproteins against erythrocyte membranes peroxidation: a comparison between healthy subjects and Type 1 diabetic patients. J Clin Endocrinol Metab 2004; 98: 2957-2962.
33. Dierckx N, Horvath G, van Gils C, Vertommen J, van de Vliet J, De Leeuw I et al. Oxidative stress status in patients with diabetes mellitus: relationship to diet. Eur J Clin Nutr 2003; 57: 999-1008.
34. Moat S, Bonham J, Cragg R, Powers H. Elevated plasma homocysteine elicits an increase in antioxidant enzyme activity. Free Rad Res 2000; 32: 171-179.
35. Munzel T, Keaney J. Are ACE inhibitors a 'magic bullet' against oxidative stress? Circulation 2001; 104: 1571-1574.
36. Malik R, Schofield I, Izzard A, Austin C, Bermann G, Heagerty A. Effects of angiotensin type-1 receptor antagonism on small artery function in patients with Type 2 diabetes mellitus. Hypertension 2005; 45: 264-269.
37. Targher G, Zenari L, Bertolini L, Falezza G, Muggeo M, Zoppini G. Plasma total homocysteine levels are associated with von Willebrand factor, soluble intercellular adhesion molecule-1, and soluble tumour necrosis factor-α receptors in young Type 1 diabetic patients without clinical evidence of macrovascular complications. Diabetes Care 2001; 24: 1496-1497.
38. Rabini R, Staffolani R, Fumelli P, Mutus B, Curatola G, Mazzanti L. Decreased nitric oxide synthase activity in platelets from IDDM and NIDDM patients. Diabetologia 1998; 41: 101-104.
39. Mutus B, Rabini RA, Staffolani R, Ricciotti R, Fumelli P, Moretti N et al. Homocysteine-induced inhibition of nitric oxide production in platelets: a study on healthy and diabetic subjects. Diabetologia 2001; 44: 979-982.